<DOC>
	<DOCNO>NCT01998126</DOCNO>
	<brief_summary>The goal overall study evaluate recommend phase 2 dose short long term toxicity combination . This modified phase I trial immune checkpoint inhibitor combination mutation - specific target therapy ( crizotinib erlotinib ) conventional dos stratify presence ALK ( Anaplastic lymphoma kinase ) EGFR ( epidermal growth factor receptor ) mutation . The goal overall study evaluate recommend phase 2 dose short long term toxicity combination .</brief_summary>
	<brief_title>Combination Checkpoint Inhibitor Plus Erlotinib Crizotinib EGFR ALK Mutated Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis Stage IV NonSmall Cell Lung Cancer ( NSCLC ) , Stages II III NSCLC treat curatively standard technique . NonSmall Cell Lung Cancer ( NSCLC ) either EGFR ALK mutate . Untreated with/or actively treat specific inhibitor le 6 month progress active therapy . Age &gt; 18 . ECOG performance status 0 , 1 2 . Prior chemotherapy allow &gt; one month end treatment . Patients must receive chemotherapy within 4 week start study drug . Brain metastases allow patient asymptomatic previous steroid treatment discontinue &gt; 6 week . Adequate bone marrow function define protocol Serum bilirubin level &lt; 1.5 mg/dL except patient Gilbert 's syndrome . Adequate organ function define protocol If female childbearing potential , documentation negative pregnancy test ( serum urine ) within 7 day prior first dose . Able provide inform consent sign approve consent form conform federal institutional guideline . Concurrent therapy nonprotocol anticancer therapy . History malignancy require active treatment . Patients history acute diverticulitis , intraabdominal abscess , Gastrointestical obstruction abdominal carcinomatosis know risk factor bowel perforation . History symptomatic autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g. , GuillainBarre Syndrome ) . History vitiligo adequately control endocrine deficiency hypothyroidism allow . Significant cardiovascular disease include : Active , clinically symptomatic leave ventricular failure . Uncontrolled symptomatic hypertension control antihypertensive agent . Myocardial infarction , severe angina , unstable angina within 6 month prior administration first dose study drug . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) Cardiac arrhythmia require antiarrhythmic medication ( except atrial fibrillation well control antiarrhythmic medication ) Coronary peripheral artery bypass graft within 6 month screen . Uncontrolled CNS metastasis allow ; subject previously treat brain metastasis allow brain metastasis treat , toxicity resolve grade 1 baseline steroid longer require . Leptomeningeal metastasis allow . Serious/active infection infection require parenteral antibiotic . Pregnant lactating female . HIV infection chronic hepatitis B C. Negative Screening test HIV , Hepatitis B , Hepatitis C require . The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place subject undue risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>